Literature DB >> 9328355

Transcriptional activation and repression by RORalpha, an orphan nuclear receptor required for cerebellar development.

H P Harding1, G B Atkins, A B Jaffe, W J Seo, M A Lazar.   

Abstract

Mutation of the orphan nuclear receptor RORalpha results in a severe impairment of cerebellar development by unknown mechanisms. We have found that RORalpha activates transcription from only a subset of sites to which it binds strongly as a monomer. RORalpha also selectively binds as a homodimer to a direct repeat of this monomer site with a 2-bp spacing between the AGGTCA sequences (Rev-DR2 site) and is a much more potent transcriptional activator on this site than on monomer sites or other direct repeats. To better understand the transcriptional regulatory functions of RORalpha, we fused its C terminus to a heterologous DNA-binding domain. Mutational analysis revealed that RORalpha contains both transcriptional activation and transcriptional repression domains, with the repression domain being more active in some cell types. The abilities of RORalpha polypeptides to repress transcription correlate with their abilities to interact with the nuclear receptor corepressors N-CoR and SMRT in vitro. However, the AF2 region of RORalpha inhibits corepressor interaction on DNA, consistent with the lack of repression by the full-length receptor. Thus, transcriptional regulation by RORalpha is complex and likely to be regulated in a cell type- and target gene-specific manner.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9328355     DOI: 10.1210/mend.11.11.0002

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  37 in total

1.  Sequence-specific transcriptional repression by KS1, a multiple-zinc-finger-Krüppel-associated box protein.

Authors:  B Gebelein; R Urrutia
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

2.  The yeast protein Xtc1 functions as a direct transcriptional repressor.

Authors:  Ana Traven; Lidija Staresincić; Milica Arnerić; Mary Sopta
Journal:  Nucleic Acids Res       Date:  2002-06-01       Impact factor: 16.971

3.  Novel mechanism of nuclear receptor corepressor interaction dictated by activation function 2 helix determinants.

Authors:  Anna N Moraitis; Vincent Giguère; Catherine C Thompson
Journal:  Mol Cell Biol       Date:  2002-10       Impact factor: 4.272

4.  Structure of a thyroid hormone receptor DNA-binding domain homodimer bound to an inverted palindrome DNA response element.

Authors:  Yi Chen; Matthew A Young
Journal:  Mol Endocrinol       Date:  2010-07-07

Review 5.  Adopting new orphans into the family of metabolic regulators.

Authors:  Sarah Hummasti; Peter Tontonoz
Journal:  Mol Endocrinol       Date:  2008-02-07

Review 6.  Nuclear receptor Rev-erbα: up, down, and all around.

Authors:  Logan J Everett; Mitchell A Lazar
Journal:  Trends Endocrinol Metab       Date:  2014-07-22       Impact factor: 12.015

7.  Nuclear receptor DAX-1 recruits nuclear receptor corepressor N-CoR to steroidogenic factor 1.

Authors:  P A Crawford; C Dorn; Y Sadovsky; J Milbrandt
Journal:  Mol Cell Biol       Date:  1998-05       Impact factor: 4.272

8.  The DRIP complex and SRC-1/p160 coactivators share similar nuclear receptor binding determinants but constitute functionally distinct complexes.

Authors:  C Rachez; M Gamble; C P Chang; G B Atkins; M A Lazar; L P Freedman
Journal:  Mol Cell Biol       Date:  2000-04       Impact factor: 4.272

9.  Fasting-induced FGF21 is repressed by LXR activation via recruitment of an HDAC3 corepressor complex in mice.

Authors:  Amena Archer; Nicolas Venteclef; Agneta Mode; Matteo Pedrelli; Chiara Gabbi; Karine Clément; Paolo Parini; Jan-Åke Gustafsson; Marion Korach-André
Journal:  Mol Endocrinol       Date:  2012-10-16

10.  REV-ERBalpha participates in circadian SREBP signaling and bile acid homeostasis.

Authors:  Gwendal Le Martelot; Thierry Claudel; David Gatfield; Olivier Schaad; Benoît Kornmann; Giuseppe Lo Sasso; Antonio Moschetta; Ueli Schibler
Journal:  PLoS Biol       Date:  2009-09-01       Impact factor: 8.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.